Crizotinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3858 publications

Uterine inflammatory myofibroblastic tumor: a clinicopathological and molecular genetic analysis of eight cases

Uterine inflammatory myofibroblastic tumor: a clinicopathological and molecular genetic analysis of eight cases

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: June 07, 2026

Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non-Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT).

Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non-Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT).

Journal: JCO global oncology

Published: June 04, 2026

Pulmonary epithelioid inflammatory myofibroblastic sarcoma with EML4::ALK gene fusion: report of a case

Pulmonary epithelioid inflammatory myofibroblastic sarcoma with EML4::ALK gene fusion: report of a case

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: April 09, 2026

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 07, 2026

Design, synthesis, and biological evaluation of BODIPY-based photoactivatable Crizotinib prodrugs for precision cancer therapy.

Design, synthesis, and biological evaluation of BODIPY-based photoactivatable Crizotinib prodrugs for precision cancer therapy.

Journal: Bioorganic & medicinal chemistry letters

Published: March 24, 2026

Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).

Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).

Journal: Virus research

Published: March 13, 2026

Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases.

Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases.

Journal: Frontiers in oncology

Published: March 08, 2026

ALK -Rearranged Renal Cell Carcinoma : Morphologic Spectrum and Genomic Landscape From a Multi-Institutional Cohort of 16 Cases.

ALK -Rearranged Renal Cell Carcinoma : Morphologic Spectrum and Genomic Landscape From a Multi-Institutional Cohort of 16 Cases.

Journal: The American journal of surgical pathology

Published: March 06, 2026

Gastrointestinal pH Gradient-Induced Phase Transition of Crizotinib: The Significance of pH-Dependent Ionization (Protonation) on Liquid-Liquid Phase Separation of a Weakly Basic Drug.

Gastrointestinal pH Gradient-Induced Phase Transition of Crizotinib: The Significance of pH-Dependent Ionization (Protonation) on Liquid-Liquid Phase Separation of a Weakly Basic Drug.

Journal: Molecular pharmaceutics

Published: March 05, 2026

Enhanced Efficacy and Safety of 177Lu-Anti-CD25 Radioimmunotherapy by Combination with Targeted Anticancer Agents.

Enhanced Efficacy and Safety of 177Lu-Anti-CD25 Radioimmunotherapy by Combination with Targeted Anticancer Agents.

Journal: Molecular pharmaceutics

Published: March 03, 2026

Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation.

Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation.

Journal: Pharmaceutical medicine

Published: March 02, 2026

ALK-tyrosine kinase inhibitor resistance due to acquired MET amplification in ALK-fusion positive advanced NSCLC effectively treated by lorlatinib-vebreltinib combination: a case report and literature review.

ALK-tyrosine kinase inhibitor resistance due to acquired MET amplification in ALK-fusion positive advanced NSCLC effectively treated by lorlatinib-vebreltinib combination: a case report and literature review.

Journal: Translational lung cancer research

Published: March 02, 2026

Showing 1-12 of 3,858

Last Updated: 06/30/2026